23 September 2015
Royal Liverpool University Hospital unveils state-of-the-art training centre in North West.
Royal Liverpool University Hospital has today unveiled a state-of-the-art training laboratory and regional centre of excellence. The site will provide training for more than 1,000 hospital and laboratory staff a year, from across the North West.
The centre, which is part of Liverpool Clinical Laboratories, was redeveloped following a grant from Roche Diagnostics, as part of its ongoing commitment to training and excellence in diagnostics.
Staff will be trained on the latest diagnostic innovations and technologies that are used at the point of care within the hospital, to provide high quality care for patients. These tests help doctors and nurses to better care for patients, who are often critically ill, by closely monitoring their condition and detecting the early signs of deterioration.
The Royal Liverpool University Hospital is the largest hospital in Merseyside and Cheshire, and provides emergency, general and specialist treatment to over 750,000 people a year across the North West.
The centre was opened by Christopher Parker, Managing Director of Roche Diagnostics UK and Ireland, to an audience of 50 people.
Jane Mills, Chief Operating Officer, Liverpool Clinical Laboratories, said: “It is often the unsung hero of medicine but up to 70 per cent of clinical decision-making is based on diagnostic testing. Ensuring doctors have access to accurate test results is an essential component of delivering the highest quality care for our patients.
Christopher Parker, Managing Director of Roche Diagnostics UK and Ireland, said: “Roche is committed to ensuring excellence in diagnostics, going beyond just the development of the latest innovations by also ensuring that all patients have timely access to safe and accurate testing.”
Notes to Editor:
For media enquiries please call +44 (0)20 7054 9974 or email email@example.com
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-eight medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.